Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study
Chemo-immunotherapy can benefit HR-NBL patients with PD before HDC, including those with progression during/at the end of the induction chemotherapy and NMYC amplification. These findings support its early inclusion in HR-NBL trials.
Authors
- Yves Réguerre (ORCID: https://orcid.org/0000-0001-7192-046X)
- Pablo Berlanga (ORCID: https://orcid.org/0000-0003-1110-7789)
- Estelle Thébaud (ORCID: https://orcid.org/0000-0003-0516-4103)
- Anne Sophie Defachelles (ORCID: https://orcid.org/0000-0002-4277-9871)
- Arnaud Petit (ORCID: https://orcid.org/0000-0001-8363-1622)
- Claudia Pasqualini (ORCID: https://orcid.org/0000-0002-1113-2792)
- Gudrun Schleiermacher (ORCID: https://orcid.org/0000-0002-0133-5879)
- Sarah Jannier (ORCID: https://orcid.org/0000-0002-6646-2473)
- Marion Gambart
- Lee Aymar Ndounga‐Diakou (ORCID: https://orcid.org/0000-0001-5979-1714)
- Stéphanie Proust
- Chrystelle Dupraz
- Salim Laghouat
Institutions
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Université Paris Sciences et Lettres (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Sorbonne Université (FR)
- Hôpital Armand-Trousseau (FR)
- Centre Hospitalier Universitaire de La Réunion (RE)
- Center for Children (US)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre d'Investigation Clinique de Nantes (FR)
- Centre Oscar Lambret (FR)
- Université d'Angers (FR)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1002/pbc.32080
- Citations
- 2
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78